PharmaVitae 2004: Bristol-Myers Squibb Global & US Analysis: Table of Contents

Table of Contents

PharmaVitae 2004: Bristol-Myers Squibb Global & US Analysis - Global and US focused analysis of Bristol-Myers Squibb's strategy, marketed portfolio, pipeline potential and financial position in 2004

Product Code: cshc1123

Price: $5700

Publication Date: 14-Jul-2004

Overview

Introduction

This analysis examines the market position and future outlook for BMS. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information

Reasons to Purchase

Benchmark BMS's performance against key rivals in the ethical pharmaceuticals sector
Understand the contribution of BMS's US versus its global operations to its forecast 2.2% CAGR in sales from 2003 to 2010
Evaluate the impact of BMS's high licensing dependence, at over 60% of sales, on the company's operations

CHAPTER 1 EXECUTIVE SUMMARY	4
Key findings	4
Current positioning: competitive outlook 2003	5
Future performance: growth drivers and resistors 2004-10	6
Evolution in therapeutic focus: 2003 - 10	8
Key issues facing Bristol-Myers Squibb: 2004 - 10	9
Strategic outlook	10
CHAPTER 2 COMPANY STRATEGY	19
Introduction to Bristol-Myers Squibb	20
Assessment of strategic position	20
Strengths	20
Weaknesses	22
Opportunities	23
Threats	24
Therapeutic foci	25
R&D productivity	26
Development opportunities	28
Organic growth	28
Partnerships/licensing	29
Mergers and acquisitions	30
Geographical expansion	31
Implications of financial position	32
CHAPTER 3 PORTFOLIO AND PIPELINE ANALYSIS	33
Therapy area focus in 2003	34
Business development by therapy area	36
Forecast revenue stream, 2004-10	38
Therapy area forecasts to 2010	38
Cardiovascular franchise	41
Marketed products	41
Pravachol (pravastatin)	42
Plavix (clopidogrel)	46
Avapro (irbesartan)	51
Monopril (fosinopril)	55
Coumadin (warfarin)	57
Capoten (captopril)	59
Questran (cholestyramine)	60
R&D compounds	60
E2F Decoy (edifoligide)	62
Factor Xa (razaxaban)	64
MaxiPost (flindokalner)	66
BMS 207940 (edonentan)	67
Vanlev (omapatrilat)	67
BMS-200980 (lanetoplase)	70
BMS-189921	70
Cardiovascular portfolio sales forecasts and forecast revenue growth	70
Oncology franchise	72
Marketed products	72
Taxol (paclitaxel)	73
Paraplatin (carboplatin)	75
Megace (megastrol acetate)	77
Ifex (ifosfamide)	78
Platinol (cisplatin)	79
VePesid (etoposide)	79
R&D compounds	80
Erbitux/IMC-C225 (cetuximab)	81
Ixabepilone (BMS-247550)	86
BMS-184476	87
BMS-214662 (farnesyl transferase inhibitor)	87
BMS-275291	87
BMS-182751/JM-216 (satraplatin)	88
Combretastatin	88
Oncology portfolio sales forecasts and forecast revenue growth	88
HIV franchise	89
Marketed products	89
Sustiva (efavirenz)	90
Zerit (stavudine /d4T)	95
Reyataz (atazanavir)	98
Videx (didanosine)	102
R&D compounds	103
DPC-083	104
BMS-488043	105
HIV portfolio sales forecasts and forecast revenue growth	107
Infectious disease franchise	108
Marketed products	108
Cefzil (cefprozil)	110
Tequin (gatifloxacin)	111
Maxipime (cefepime)	113
R&D compounds	114
Entecavir/BMS 200475	115
Ravuconazole/BMS-207147	116
Garenoxacin/desquinolone (BMS-284756)	117
Infectious disease portfolio sales forecasts and forecast revenue growth	119
CNS franchise	119
Marketed products	119
Abilify (aripiprazole)	120
Sinemet (levodopa + carbidopa)	124
Serzone (nefazodone)	125
BuSpar (buspirone)	125
R&D compounds	126
BMS-347070	127
CNS portfolio sales forecasts and forecast revenue growth	127
Diabetes and endocrinology franchise	128
Marketed products	128
Glucophage (metformin)/Glucophage XR /Glucovance (metformin and glyburide)	128
Metaglip (glipizide and metformin)	131
R&D compounds	132
Muraglitazar (BMS-298585)	133
Basulin	134
Inhaled insulin	134
Diabetes and endocrinology sales forecasts and forecast revenue growth	136
Other products	137
Marketed products	137
R&D compounds	138
abatacept (CTLA4-Ig)	139
LEA29Y	141
Other sales forecasts and forecast revenue growth	142
CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE	143
US Company Strategy	144
US marketing strategies	144
US Portfolio and pipeline analysis	145
US therapy area focus in 2003	145
Forecast US revenue stream, 2004-10	146
US therapy area forecasts to 2010	146
Cardiovascular franchise	148
Oncology franchise	150
HIV franchise	151
CNS franchise	152
Infectious disease franchise	153
Diabetes & endocrinology	154
Other franchise	155
CHAPTER 5 CORPORATE DEVELOPMENT	157
Financial position, 2002 - 2003	158
Financial position, 2002 - 2003	158
Revenue growth	158
Cost structure and profitability	159
Liquidity, 1999-2003	160
2003 performance benchmarking	161
Business model clustering according to 2003 cost ratios	161
2003 growth and investment momentum	163
Key events shaping corporate activity, 2002-2003	165
Corporate alliances and deals	165
Solvay	166
Kereos	166
ChainDrugStore.net	167
Lexicon Genetics	167
Exelixis	167
Novartis	168
Fujisawa	168
Corgentech	168
Sequenom	168
CHAPTER 6 APPENDIX : SUPPORTING DATA	170
Financial data	170
Exchange rates	170
Methodology for therapy area forecasting	171
List of Tables
Table 1: Breakdown of Bristol-Myers Squibb's ethical sales by therapy area, 2002-03	34
Table 2: Forecast sales for Bristol-Myers Squibb's major therapy areas, 2004-10	39
Table 3: Bristol-Myers Squibb's marketed cardiovascular portfolio	41
Table 4: Bristol-Myers Squibb's cardiovascular R&D pipeline, 2004	61
Table 5: Forecast sales for Bristol-Myers Squibb's cardiovascular portfolio, 2004-10	71
Table 6: Bristol-Myers Squibb's marketed oncology portfolio	72
Table 7: Bristol-Myers Squibb's oncology R&D pipeline, 2004	80
Table 8: Forecast sales for Bristol-Myers Squibb's oncology portfolio, 2004-10	89
Table 9: Bristol-Myers Squibb's marketed HIV portfolio	90
Table 10: Bristol-Myers Squibb's HIV R&D pipeline, 2004	103
Table 11: Forecast sales for Bristol-Myers Squibb's HIV portfolio, 2004-10	108
Table 12: Bristol-Myers Squibb's marketed infectious disease portfolio	109
Table 13: Bristol-Myers Squibb's infectious disease R&D pipeline, 2004	114
Table 14: Forecast sales for Bristol-Myers Squibb's infectious disease portfolio, 2004-10	119
Table 15: Bristol-Myers Squibb's marketed CNS portfolio	120
Table 16: Bristol-Myers Squibb's CNS R&D pipeline, 2004	126
Table 17: Forecast sales for Bristol-Myers Squibb's CNS portfolio, 2004-10	127
Table 18: Bristol-Myers Squibb's marketed diabetes and endocrinology portfolio	128
Table 19: Bristol-Myers Squibb's diabetes & endocrinology R&D pipeline, 2004	132
Table 20: Forecast sales for Bristol-Myers Squibb's diabetes and endocrinology portfolio, 2004-10	136
Table 21: Bristol-Myers Squibb's other marketed products	138
Table 22: Bristol-Myers Squibb's other R&D products, 2004	139
Table 23: Forecast sales for Bristol-Myers Squibb's other portfolio, 2004-10	142
Table 24: Breakdown of Bristol-Myers Squibb's US ethical sales by therapy area, 2002-03	145
Table 25: Forecast US sales for Bristol-Myers Squibb's major therapy areas, 2004-10	147
Table 26: Forecast US sales for Bristol-Myers Squibb's cardiovascular portfolio, 2004-10	149
Table 27: Forecast US sales for Bristol-Myers Squibb's oncology portfolio, 2004-10	150
Table 28: Forecast US sales for Bristol-Myers Squibb's HIV portfolio, 2004-10	152
Table 29: Forecast US sales for Bristol-Myers Squibb's infectious disease portfolio, 2004-10	153
Table 30: Forecast US sales for Bristol-Myers Squibb's infectious disease portfolio, 2004-10	154
Table 31: Forecast US sales for Bristol-Myers Squibb's diabetes & endocrinology portfolio, 2004-10	155
Table 32: Forecast US sales for Bristol-Myers Squibb's diabetes & endocrinology portfolio, 2004-10	156
Table 33: Bristol-Myers Squibb's revenues by division, 2002-03	158
Table 34: Bristol-Myers Squibb's operating expenses, 2002-03	159
Table 35: Summary of Bristol-Myers Squibb's historical agreements, 2003-04	165
Table 36: Exchange rates, 2003	170
List of Figures
Figure 1: Competitive positioning of Bristol-Myers Squibb within the pharmaceutical market, 2003	5
Figure 2: Bristol-Myers Squibb's growth drivers and resistors, 2004-10	6
Figure 3: BMS's changing therapeutic focus, 2003-10	8
Figure 4: BMS's high dependence on partner companies to source its products affects the company's profitability, as it has to repay much of its sales to the originator company, as royalty payments	9
Figure 5: Assessment of Bristol-Myers Squibb's strategic position, 2004	10
Figure 6: Breakdown of Bristol-Myers Squibb's sales by region, 2002-03	31
Figure 7: Bristol-Myers Squib's ethical sales breakdown, 2003	36
Figure 8: Bristol-Myers Squibb's business development by therapy area	37
Figure 9: Forecast sales for Bristol-Myers Squibb's major therapy areas, 2004-10	40
Figure 10: BMS's licensing dependence in the US market	144
Figure 11: BMS's ethical sales breakdown for the US market, 2003	146
Figure 12: Forecast US sales for Bristol-Myers Squibb's major therapy areas, 2004-10	148
Figure 13: Bristol-Myers Squibb's liquid assets versus total liabilities,1999-2003	160
Figure 14: R&D and S,G&A spend and COGS as a proportion of revenue, 2003	162
Figure 15: Benchmarking of financial strength, 2003	164

Contact Datamonitor on:

Datamonitor USA	Datamonitor Europe	Datamonitor Germany	Datamonitor Asia Pacific	Datamonitor Japan
245 Fifth Ave	Charles House	Kastor & Pollux	Darling Park	Wakamatsu Bldg 7F
4th Floor	108-110 Finchley Road	Platz der Einheit 1	Tower 2, Level 21	3-3-6 Nihonbashi-Honcho
New York, NY 10016	London NW3 5JJ	60327 Frankfurt	201 Sussex Street	Chuo-ku
USA	United Kingdom	Deutschland	Sydney, NSW 2000	Tokyo 103-0023
			Australia	Japan

t: +1 212 686 7400	t: +44 20 7675 7000	t: +49 69 9750 3119	t: +61 2 9006 1526	t: +81 3 6202 7681
f: +1 212 686 2626	f: +44 20 7675 7500	f: +49 69 9750 3320	f: +61 2 9006 1559	f: +81 3 4512 8117
e: usinfo@datamonitor.com	e: eurinfo@datamonitor.com	e: deinfo@datamonitor.com	e: apinfo@datamonitor.com	e: jpinfo@datamonitor.com

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that Datamonitor delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such Datamonitor can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

This report is a licensed product and is not to be photocopied